Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.59 |
| ▸ | TACR3 | P29371 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | FPR1 | P21462 | 1/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22076806 | 1.00 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL21391935 | 0.95 | TACR1 (0.57) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL20473749 | 0.91 | TACR1 (0.60) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL1901932 | 0.89 | TACR1 (0.48) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL22076807 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL17837327 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL30861885 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL156378 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL1932400 | 0.88 | TACR1 (0.57) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL21955651 | 0.85 | TACR1 (0.71) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088743-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2012-04-12 | — | — | US | disclosed |
| US-20120071452-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS | GRAS ESCARDO JORDI (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120059031-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2012-03-08 | — | — | US | disclosed |
| US-20120040943-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | GRAS ESCARDO JORDI (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20110224177-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | GRAS ESCARDO JORDI | 2011-09-15 | — | — | US | disclosed |
| WO-2011057757-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-05-19 | — | — | WO | disclosed |
| EP-2319538-A2 | Combinations combrising antimuscarinic agents and corticosteroids | Almirall S.A. (ES) | 2011-05-11 | — | — | EP | disclosed |
| EP-2292267-A2 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | Almirall S.A. (ES) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| US-20110021476-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ESCARDO JORDI GRAS | 2011-01-27 | — | — | US | disclosed |
| US-20110021477-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS | GRAS ESCARDO JORDI | 2011-01-27 | — | — | US | disclosed |
| US-20110021478-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021476-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, CHRM4, PDE4A | TACR1 121/4885TACR3 125/4885NR3C1 1509/4885 |
| US-20110021477-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS | CHRM3, CHRM2, NR3C2 | TACR1 90/4885TACR3 213/4885NR3C1 11/4885 |
| US-20120071452-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTERIODS | CHRM3, CHRM2, NR3C2 | TACR1 90/4885TACR3 213/4885NR3C1 11/4885 |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAPKAPK2, MAPK7 | TACR1 3781/4885TACR3 4517/4885NR3C1 1228/4885 |
| US-20120040943-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20110021478-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 213/4885NR3C1 591/4885 |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | TACR1 1430/4885TACR3 3342/4885NR3C1 565/4885 |
| US-20120059031-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, CHRM4, PDE4A | TACR1 121/4885TACR3 125/4885NR3C1 1509/4885 |
| US-20110224177-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | CHRM3, CHRM2, CHRM5 | TACR1 65/4885TACR3 103/4885NR3C1 34/4885 |
| US-20120088743-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | TACR1 159/4885TACR3 207/4885NR3C1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.